Danaher Q3 adjusted EPS beats, FY guidance raised
DHR•Danaher reported Q3 revenue of $6.55 billion, slightly below the $6.56 billion consensus, while adjusted EPS of $2.11 topped the $1.92 estimate. The company raised its 2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60.
1. Quarterly results
Danaher’s Q3 revenue rose 8.5% to $6.55 billion, slightly missing analyst expectations of $6.56 billion. Adjusted EPS grew 11.5% to $2.11, beating the $1.92 consensus, while EPS was $1.71 and operating cash flow was $1.90 billion.
2. Raised outlook
Danaher raised its 2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60. For Q4, it expects non-GAAP core revenue excluding respiratory revenue to rise 4%-5% year over year, and core revenue growth of about 3% including the respiratory revenue headwind.
3. Growth drivers
The company said faster core revenue growth excluding respiratory revenue helped drive Q3 results. Its CEO cited improving trends across end markets as contributing to better-than-expected revenue, earnings and cash flow, and Danaher attributed its financial performance to execution of the Danaher Business System.
